HOW TO ORDER A TEST

Order the OncoNext™ Liquid test shipping kit from Genoma Group

Schedule a patient blood draw. Fasting is not required prior to a OncoNext Liquid test

Draw a blood sample (10 ml)

Fill in all required TFR information and enclose the informed consent signed from the patient

Prepare and ship the sample to Genoma for analysis.

Interpretive test report is provided to the physician within 15 days

ONCO NEXT LIQUID
Next Generation Oncology Diagnostics

ONCO NEXT RISK
Next Generation Oncology Diagnostics

Detects germline mutations involved in genetic predisposition to cancer

ONCO NEXT LIQUID
Next Generation Oncology Diagnostics

Analysis of circulating tumour DNA (ctDNA) for cancer detection and monitoring (liquid biopsy)

ONCO NEXT TISSUE
Next Generation Oncology Diagnostics

Detects somatic mutations in tumor DNA (tDNA) from tissue samples (traditional biopsy)

ONCONEXT™: ADVANCED MOLECULAR DIAGNOSTICS SOLUTIONS USING STATE-OF-THE-ART TECHNOLOGIES

- **Test performed in Italy** (Rome or MIlan)
- Fast TAT: **15 days**
- **20 years experience** in molecular diagnostics
- Personalized **genetic counseling** with genetic counselors experts in discussing genetic test results and familial risks.
- Laboratories **ISO 17025** accredited with groundbreaking technologies
- Test available **worldwide**
- Over **200.000** genetic tests/year
- **Dedicated R&D team** Numerous peer-reviewed papers published in renowned international journals

Onconext Liquid T ENG rev.01

design by evermind.it

eurofins | Genoma

Eurofins Genoma Group sole shareholder limited liability company

ONCO NEXT
Next Generation Oncology Diagnostics

www.laboratoriogenoma.eu
www.onconext.it

ROMA
Laboratories and Medical Offices

Via Castel Giubileo, 11 – 00138 Roma (RM)
Tel.: + (39) 06 8811270 (6 PBX lines)
Fax: +(39) 06 64492025
E-mail: info@laboratoriogenoma.eu

MILANO
Laboratories and Medical Offices

Via Enrico Cialdini, 16 (Affori Centre) – 20161 Milano (MI)
Tel.: + (39) 02 39297626 (12 PBX lines)
Fax: + (39) 02 392976261
E-mail: info@genomamilano.it

ONCO NEXT LIQUID
Next Generation Oncology Diagnostics

Liquid biopsy for detection of somatic mutations in circulating cell-free tumor DNA (ctDNA) from a blood sample

PERSONALIZING CANCER CARE

MONITORING RESIDUAL DISEASE

"Liquid biopsy" is a non-invasive, highly sensitive and cost effective method of isolating and detecting cfDNA fragments, including circulating tumor DNA (ctDNA), from the plasma of patients diagnosed with cancer or from individuals who may have cancer. **By analyzing cell-free DNA** isolated from a patient's blood, we can identify clinically relevant genomic alterations in ctDNA and match these alterations to targeted therapies and clinical trials.

TUMOR BIOPSY	ONCONEXT LIQUID
Invasive and expensive	Non-invasive and less expensive
Specific to localized tumor site	Less dependent on original tumor site since tumor from both primary and metastatic sites release DNA into the bloodstream
Assessment of tumor heterogeneity limited to section of biopsy analyzed	Can capture tumor heterogeneity
Difficult to biopsy some organs	Easy to collect sample from blood
Not viable if primary tumor has been resected or if the tumor cannot be easily visualized via imaging studies	Allows for serial evaluation in absence of detectable primary tumor or metastases
A limited amount of tissue may be obtained for immunohistochemical and genomic analysis	A few copies of mutant ctDNA are sufficient for analysis
Serial biopsies are difficult to tolerate	Patient can tolerate serial blood draws for evaluation; may lead to greater compliance
	New tool that can be applied for evaluation of response to therapy and for detection of residual disease
	May allow for evaluation of development of resistance
	May aid in early detection of cancer

ONCONEXT LIQUID offers a potential alternative to surgical tumor biopsy and histological assessment, eliminating many of the difficulties and concerns associated with traditional tests, as well as a means of augmenting imaging studies and other diagnostic methods

MONITORING RECURRENCE

ONCONEXT LIQUID Next Generation Oncology Diagnostics

MONITOR

Detection of somatic mutations on circulating tumour DNA (ctDNA) for cancer monitoring

OncoNext Liquid™ Monitor test is meant for patients who have been diagnosed with cancer

Benefits provided by ONCONEXT LIQUID Monitor

MONITOR

PATIENTS UNDERGOING CANCER TREATMENT

- Provide tumor profiling for precision medicine
- Monitor treatment efficacy and resistance
- Monitor disease progression and tumor evolution
- Clinical Trial Matching

PATIENTS AFTER CANCER TREATMENT

- Monitor residual disease
- Monitor disease recurrence
- Help the physician explore other options of treatment when the patient is resistant to current therapies

OncoNext™ Liquid Monitor provides physicians actionable biomarker information to help guide treatment and find ongoing clinical trials for aggressive, metastatic, and refractory cancer patients

ONCONEXT LIQUID test looks at a panel of genes known to be somatically altered in cancer, to identify genetic alterations that may be treated with targeted therapies.

Breast	Colon	Lung
The test looks at a panel of **10 genes** known to be somatically altered in breast cancer	The test looks at a panel of 14 genes known to be somatically altered in colorectal cancer	The test looks at a panel of 11 genes known to be somatically altered in lung cancer
ONCONEXT LIQUID Monitor **15 genes**	ONCONEXT LIQUID Monitor **23 genes**	ONCONEXT LIQUID Monitor **50 genes**

Genoma Group also offers oncogene panels tailored for specific indications. Contact Genoma to learn more.

A broad base of high-priority target genes are used in all OncoNext™ Liquid Monitor tests, regardless of which mutations were originally detected in the patient's tumor. This allows detection of arising clones that may create resistance to current therapies or reveal options for additional targeted therapies,

EARLY DETECTION OF CANCER

ONCONEXT LIQUID Next Generation Oncology Diagnostics

SCAN

Detection of somatic mutations on circulating tumour DNA (ctDNA) for early detection of cancer

OncoNext Liquid™ Scan is meant for preventive surveillance of high-risk populations

Benefits provided by ONCONEXT LIQUID Scan

SCAN

PATIENTS WITH A SUSPECTED CANCER

Identification of somatic mutations in genes known to be altered in cancer, confirming the suspect of disease

HIGH RISK PATIENTS

Detection of somatic mutations in genes known to be altered in cancer, that could indicate early disease

EXAMPLES OF HIGH RISK POPULATIONS INCLUDE, BUT ARE NOT LIMITED TO:

- Known genetic predisposition to a specific cancer (e.g. the individual carries a BRCA1 mutation);
- Significant family history of cancer;
- Personal history of smoking;
- Exposure to known carcinogens (e.g. radon);
- Prolonged radiation or UV light exposure;
- History of hormone use (fertility drugs, progestogen-containing hormone replacement therapy)



ONCONEXT LIQUID Scan test is designed to screen a set of cancer driver genes for somatic mutations that could indicate early disease:

ONCONEXT LIQUID Scan **15 genes**	ONCONEXT LIQUID Scan **23 genes**	ONCONEXT LIQUID Scan **50 genes**

MONITORING DRUG RESISTANCE

MONITORING TREATMENT EFFECTIVENESS

DEVELOPMENT OF A PERSONALIZED TREATMENT PLAN